A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

March 12, 2024

Study Completion Date

February 27, 2026

Conditions
Pulmonary Arterial Hypertension
Interventions
BIOLOGICAL

Sotatercept

SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.

Trial Locations (17)

1608582

Keio university hospital ( Site 2007), Tokyo

7378505

Kure Kyosai Hospital ( Site 2017), Kure

466-8560

Nagoya University Hospital ( Site 2010), Nagoya

275-8580

Chiba Saiseikai Narashino hospital ( Site 2004), Narashino

830-0011

Kurume University Hospital ( Site 2014), Kurume

060-8543

Sapporo Medical University Hospital ( Site 2018), Sapporo

060-8648

Hokkaido University Hospital ( Site 2001), Sapporo

650-0017

Kobe University Hospital ( Site 2012), Kobe

980-8574

Tohoku University Hospital ( Site 2002), Sendai

564-8565

National Cerebral and Cardiovascular Center ( Site 2011), Suita

431-3192

Hamamatsu University Hospital ( Site 2016), Hamamatsu

113-8654

The University of Tokyo Hospital ( Site 2006), Bunkyo-ku

181-8611

Kyorin University Hospital ( Site 2005), Mitaka

260-8677

Chiba University Hospital ( Site 2003), Chiba

812-8582

Kyushu University Hospital ( Site 2015), Fukuoka

701-1192

National Hospital Organization Okayama Medical Center ( Site 2013), Okayama

108-8329

International University of Health and Welfare Mita Hospital ( Site 2008), Tokyo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT05818137 - A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) | Biotech Hunter | Biotech Hunter